platoseedplatoseed
Combinations therapy by rational design
Serinus Biosciences is tackling one of the toughest problems in cancer treatment: creating combination therapies to override treatment resistance. We leverage cutting edge technology to design a fully explainable AI platform primed with decades of system biology knowledge. Uniquely powered for biological inference, our AI engine uncovers how cancer cells evolve treatment resistance and identifies molecules to overcome resistance escape routes. We design combinations that are safer, more effective, and can get to patients quickly. Founded by MIT PhDs and supported by a scientific advisory board of top academics from the Broad Institute, Dana-Farber, and UCSD, Serinus is powered by Y Combinator and other top investors to revolutionize precision medicine.
Serinus Biosciences focuses on combination therapies delivered through rational design. The company presents itself as a bioscience startup working on therapeutic combinations, with contact and location details provided on its site.</summary>
The site indicates a focus on combination therapies designed through rational design principles. Specific product mechanics, such as the platform, workflow, or methods for selecting and optimizing combinations, are not described on the provided text.
Who it’s for: biotech/pharmaceutical researchers and developers, therapeutic developers, and biotech startups seeking rationally designed combination therapies
0 New Website Coming Soon; contact information listed; physical address provided
Prior to founding Serinus, Adam gained over 10 years of entrepreneurship experience including a Microsoft R&D Fellowship and Flagship Pioneering Ideation Fellowship. Adam is passionate about developing advanced AI models for biological research that will bring medicine to scale. Adam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and dual major BSc in computer science and neuroscience from Bar-Ilan University.
After five years as a paramedic, Max left clinical medicine to develop new treatments for the millions of patients without access to effective medications. He studied applied math and biology at Brown University, statistics at Cambridge University, and is completing his PhD in computational biology at MIT. His research has appeared in prestigious journals including Science, Nature Biotechnology, and Nature Neuroscience and has been recognized with national and international awards.
We develop drugs effective against multiple types of cancer... and we do it really fast! 🏃🏽
Serinus Biosciences develops cancer drugs that target shared cancer-system disruptions across patients, aiming to treat multiple cancer types quickly. They announce a platform that identifies relay support proteins in cancer cells to shut down common dysfunctional systems, with a pipeline they say could help more than 100,000 patients per year.
From the original launch (Aug 2022) — may be outdated.
Genetic Medicine with Small Molecules
Using the immune system to cure disease
